{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:50:29Z","timestamp":1772758229854,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,5,5]],"date-time":"2005-05-05T00:00:00Z","timestamp":1115251200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold>Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high\u2010titre inhibitors, and for the probabilities of success at two time points (8\u201312 and 24\u2003h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21\u2003000, compared with $33\u2003400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2005.01098.x","type":"journal-article","created":{"date-parts":[[2005,5,5]],"date-time":"2005-05-05T14:30:19Z","timestamp":1115303419000},"page":"261-269","source":"Crossref","is-referenced-by-count":22,"title":["A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high\u2010titre inhibitors"],"prefix":"10.1111","volume":"11","author":[{"given":"K. G.","family":"Putnam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. L.","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. M.","family":"Ewenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. C.","family":"Winkelmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Avorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,5,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00037.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost\u2010effectiveness in Health and Medicine","author":"Gold M","year":"1996"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/ajhp\/57.15.1403","article-title":"Coagulation products and their uses","volume":"57","author":"Shord S","year":"2000","journal-title":"Am J Health System Pharm"},{"key":"e_1_2_6_5_2","volume-title":"Data [program]","author":"TreeAge Software Inc","year":"1988"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7001.376"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2003.11.002"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1123"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199008000-00009"},{"issue":"3","key":"e_1_2_6_10_2","first-page":"12","article-title":"Workshop 2: efficacy, safety and treatment cost considerations","volume":"3","author":"Lusher J","year":"1997","journal-title":"Haemophilia"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615097"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.3111\/200205119133"},{"key":"e_1_2_6_13_2","article-title":"Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia A and inhibitors (Cochrane Review)","author":"Hind D","year":"2004","journal-title":"The Cochrane Library"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V56.6.978.978"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1542\/peds.62.5.767","article-title":"Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies","volume":"62","author":"Buchanan G","year":"1978","journal-title":"Pediatrics"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V61.1.36.36"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30790385521.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.5.1135.1135"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656122"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198109243051301"},{"key":"e_1_2_6_21_2","first-page":"405","article-title":"Early experience with the use of anti\u2010inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII","volume":"9","author":"Kantrowitz J","year":"1987","journal-title":"Clin Ther"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615388"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00209.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01128.x"},{"issue":"1","key":"e_1_2_6_25_2","first-page":"143","article-title":"American experience with home use of NovoSeven: recombinant factor VIIa in hemophiliacs with inhibitors","volume":"26","author":"Shapiro A","year":"1996","journal-title":"Haemostasis"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2005.01098.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2005.01098.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T16:31:03Z","timestamp":1706200263000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2005.01098.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1111\/j.1365-2516.2005.01098.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2005.01098.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}